Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31199
Title: Bleeding Tolerance Among Patients With Atrial Fibrillation on Oral Anticoagulation
Authors: Rusin, Gabriela
Konieczynska, Malgorzata
Bijak, Piotr
DESTEGHE, Lien 
HEIDBUCHEL, Hein 
Malinowski, Krzysztof Piotr
Undas, Anetta
Issue Date: 2020
Publisher: ELSEVIER SCIENCE INC
Source: CANADIAN JOURNAL OF CARDIOLOGY, 36 (4) , p. 500 -508
Abstract: Background: Oral anticoagulation increases the bleeding risk. We investigated how clinical factors and the level of atrial fibrillation (AF) knowledge affect the bleeding acceptance in patients with AF. Methods: In 173 consecutive anticoagulated outpatients with AF (aged 68.7 +/- 10.7 years, 39.3% male), the bleeding ratio was assessed based on the declared maximum number of major bleeds the people were willing to endure to avert 1 stroke. The Jessa AF Knowledge Questionnaire was used to assess the knowledge of AF. Results: Compared with patients with the high bleeding ratio (>= 4 accepted bleedings, n = 88, 50.9%), subjects with the low bleeding ratio (0-3 accepted bleedings, n = 85, 49.1%) were older, with longer duration of AF, suffered more commonly from heart failure, and were free of cerebrovascular events. Patients after major bleeding (n = 33, 19.1%) and those reporting minor bleeds on anticoagulation (n = 77, 44.5%) had lower bleeding ratio. The independent predictors of the low bleeding ratio were older age (odds ratio [OR], 2.50; 95% confidence interval [CI], 1.69-3.70), major bleeds on anticoagulation (OR, 3.33; 95% CI, 1.16-10.0), minor bleeds on anticoagulation (OR, 3.45; 95% CI, 1.67-7.14), and prior stroke/transient ischemic attack (OR, 0.47; 95% CI, 0.22-0.99). The level of knowledge of AF did not affect the bleeding ratio. Conclusions: The key determinants of the bleeding ratio among anticoagulated patients with AF are age, and prior thromboembolic and bleeding episodes. The study could support identification of patients with AF who need additional effort to increase their acceptance of a life-long oral anticoagulation therapy.
Notes: Undas, A (reprint author), Jagiellonian Univ Med Coll, Inst Cardiol, 80 Pradnicka St, PL-31202 Krakow, Poland.
mmundas@cyf-kr.edu.pl
Other: Undas, A (reprint author), Jagiellonian Univ Med Coll, Inst Cardiol, 80 Pradnicka St, PL-31202 Krakow, Poland. mmundas@cyf-kr.edu.pl
Keywords: Stroke Prevention;Antithrombotic Therapy;Guidelines;Management;Warfarin;Risk;Metaanalysis;Knowledge
Document URI: http://hdl.handle.net/1942/31199
ISSN: 0828-282X
e-ISSN: 1916-7075
DOI: 10.1016/j.cjca.2019.09.004
ISI #: WOS:000522860600014
Rights: 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
Category: A1
Type: Journal Contribution
Validations: ecoom 2021
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
rusin.pdf
  Restricted Access
Published version988.39 kBAdobe PDFView/Open    Request a copy
Show full item record

SCOPUSTM   
Citations

2
checked on Sep 7, 2020

WEB OF SCIENCETM
Citations

7
checked on Apr 22, 2024

Page view(s)

18
checked on Mar 29, 2022

Download(s)

2
checked on Mar 29, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.